(Q37855515)

24 August 2017

1 reference

title

Genetic and epigenetic changes in lung carcinoma and their clinical implications (English)

1 reference

24 August 2017

1 reference

1 reference

4

Ming Guo

1 reference

24 August 2017

Jing Wen

1

1 reference

24 August 2017

Jianhua Fu

series ordinal

2

1 reference

24 August 2017

Wei Zhang

series ordinal

3

1 reference

24 August 2017

publication date

18 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

24

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

932-943

1 reference

24 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

The new World Health Organization classification of lung tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Epidemiology of Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Characterizing the cancer genome in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Molecular damage in the bronchial epithelium of current and former smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Lung cancer in never smokers: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

The role of individual susceptibility in cancer burden related to environmental exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Prognostic impact of p53 protein overexpression in patients with node-negative lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

EGFR and erbB2 mutation status in Japanese lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Somatic mutations of the ERBB4 kinase domain in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

LKB1; linking cell structure and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

LKB1 mutation in large cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

LKB1 modulates lung cancer differentiation and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Prevalence and specificity of LKB1 genetic alterations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Lung cancer: from single-gene methylation to methylome profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Aberrant methylation of FBN2 in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Effect of IFN-beta on human glioma cell lines with temozolomide resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Aberrant methylation of SPARC in human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

DNA methylation markers and early recurrence in stage I lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Methylation of RAS association domain family protein 1A as a biomarker of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Global histone modifications predict prognosis of resected non small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Global levels of histone modifications predict prognosis in different cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

The epigenome as a target for cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

HDAC family: What are the cancer relevant targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Histone deacetylase 1 mRNA expression in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MicroRNA signatures in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Let-7a elevates p21(WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MicroRNA-183 regulates Ezrin expression in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MicroRNA classifiers for predicting prognosis of squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Unique microRNA molecular profiles in lung cancer diagnosis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

MicroRNA signature predicts survival and relapse in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

Clonal genetic alterations in the lungs of current and former smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

ErbB4 expression and mutation in Japanese patients with lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.46

7 January 2021

10.1038/MODPATHOL.2011.46

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1036438024

0 references

1 reference